We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Stripped Heart Matrix Supports Growth of Rejection-Free Replacement Organ

By LabMedica International staff writers
Posted on 21 Mar 2016
A team of bioengineers used a decellularized heart matrix as scaffolding to rebuild the organ for transplantation without immune markers that would prime the organ for rejection.

Investigators at Massachusetts General Hospital (Boston, USA) had demonstrated the feasibility of this approach using rat hearts. More...
In the current study, they sought to upscale the method to accommodate human hearts.

The procedure involved stripping cellular components from donor hearts that had been found to be unsuitable for transplantation. The remaining extracellular matrix scaffold, which did not contain any immune markers, could then be seeded with organ-appropriate cell types. To prevent rejection by the potential recipient of the organ, seed cardiomyocytes were derived from induced pluripotent stem cells (iPSCs) that had been generated from the patient's skin cells.

The investigators repopulated the native human cardiac matrix with stem-cell derived cardiomyocytes and generated tissues of increasing three-dimensional complexity. They maintained such cardiac tissue constructs in culture for 120 days to demonstrate definitive sarcomeric structure, cell and matrix deformation, contractile force, and electrical conduction. Under culture conditions that mimicked those within the human body, the seeded constructs developed force-generating myocardial tissue and showed electrical conductivity, left ventricular pressure development, and metabolic function.

Summarizing their results in the January 8, 2016, issue of the journal Circulation Research, the investigators stated that native cardiac extracellular matrix scaffolds maintained matrix components and structure to support the seeding and engraftment of human iPSCs–derived cardiomyocytes and enabled the bioengineering of functional human myocardial-like tissue of multiple complexities.

"Generating functional cardiac tissue involves meeting several challenges," said first author Dr. Jacques Guyette, a postdoctoral research fellow at Massachusetts General Hospital. "These include providing a structural scaffold that is able to support cardiac function, a supply of specialized cardiac cells, and a supportive environment in which cells can repopulate the scaffold to form mature tissue capable of handling complex cardiac functions."

"Regenerating a whole heart is most certainly a long-term goal that is several years away, so we are currently working on engineering a functional myocardial patch that could replace cardiac tissue damaged due a heart attack or heart failure," said Dr. Guyette. "Among the next steps that we are pursuing are improving methods to generate even more cardiac cells—recellularizing a whole heart would take tens of billions—optimizing bioreactor-based culture techniques to improve the maturation and function of engineered cardiac tissue, and electronically integrating regenerated tissue to function within the recipient's heart."

Related Links:

Massachusetts General Hospital



Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hybrid Pipette
SWITCH
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.